The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer

The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer

Gemcitabine is used to treat pancreatic cancer (PC), but is not curative. We sought to determine whether gemcitabine + a BET bromodomain inhibitor was superior to gemcitabine, and identify proteins that may contribute to the efficacy of this combination. This study was based on observations that cel...

Full description

Bibliographic Details
Main Authors: Aubrey L. Miller, Patrick L. Garcia, Samuel C. Fehling, Tracy L. Gamblin, Rebecca B. Vance, Leona N. Council, Dongquan Chen, Eddy S. Yang, Robert C. A. M. van Waardenburg, Karina J. Yoon
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Cancers
Subjects:
pancreatic ductal adenocarcinoma
gemcitabine
BET bromodomain inhibitor
JQ1
combination therapy
HMGCS2
Online Access:https://www.mdpi.com/2072-6694/13/14/3470

Internet

https://www.mdpi.com/2072-6694/13/14/3470

Similar Items